Complex pathophysiology and manifestations of EoE
Chronic nature of EoE and the impact on patient quality of life
Emerging treatments for EoE and their impact on clinical practice
Video Player Controls:
Dr Evan Dellon considers the latest data on EoE from AAAAI 2022 and how this might impact current approaches to patient care.
Dr Stuart Carr considers the latest data on EoE from AAAAI 2022 and how this might impact current approaches to patient care.
Dr Alexandra Papadopoulou considers the latest data on EoE from AAAAI 2022 and how this might impact current approaches to patient care.
Please Select A Video:
Learning Objectives & Overview
In this activity, Dr Evan Dellon reviews key data from the AAAAI 2022 Annual Meeting on eosinophilic oesophagitis. Dr Dellon is interviewed alongside Dr Stuart Carr and Dr Alexandra Papadopoulou, and our three experts share their personal insights on how these data may impact clinical practice.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of adult and paediatric gastroenterologists, adult and paediatric allergists/immunologists, paediatricians, advanced nurse practitioners, physician assistants and practice nurses involved in the management of patients with eosinophilic oesophagitis.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Evan Dellon discloses: Consultant for Abbott Laboratories, AbbVie, Adare/Ellodi Pharmaceuticals, Aimmune, Allakos, Amgen, Arena Pharmaceuticals, AstraZeneca, Avir Pharma, Biorasi, Calypso Biotech, Celgene/Receptos/Bristol Myers Squibb, Celldex Therapeutics, Eli Lilly and Co., EsoCap Biotech, GlaxoSmithKline, Gossamer Bio, InveniAI, Landos Biopharma, Lucid Diagnostics, Morphic Therapeutic, Nutricia, Parexel Informatics/Calyx Solutions, Phathom Pharmaceuticals, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Robarts/Alimentiv Inc., Salix Pharmaceuticals, Sanofi, Shire/Takeda and Target RWE. Grants/research support from Adare/Ellodi Pharmaceuticals, Allakos, Arena Pharmaceuticals, AstraZeneca, Banner and Holoclara, Inc., Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Meritage Pharma, Miraca Life Sciences, Nutricia, Regeneron Pharmaceuticals and Shire/Takeda.
Dr Stuart Carr discloses: Speaker’s bureau fees from Sanofi, Tribute/Aralez Pharmaceuticals.
Dr Alexandra Papadopoulou discloses: Advisory board or panel fees from Adare Pharmaceuticals, Dr. Falk Pharma GmbH and Specialty Therapeutics (relationships terminated). Grant/research support from AbbVie, Dr. Falk Pharma GmbH and Takeda; AstraZeneca and United Pharmaceuticals. Speaker’s bureau fees from Nestle and Petsiavas; Cross Pharmaceuticals and Uni-Pharma S.A. Pharmaceutical Laboratories (relationships terminated).
Patrick Brady, MD. has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact firstname.lastname@example.org
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 12 April 2022. Date credits expire: 12 April 2023.
If you have any questions regarding credit please contact email@example.com
After watching this activity, participants should be better able to:
- Summarize recent clinical evidence on the complex pathophysiology and manifestations of eosinophilic oesophagitis (EoE)
- Outline the chronic nature of EoE and the impact on patient quality of life
- Assess the latest data for emerging treatments for EoE and their impact on clinical practice